Anthony Quinn

This profile gathers the share dealings of Anthony Quinn across 2 companies, led by Trimeris Inc and Spyre Therapeutics, Inc. Over a trading history stretching from 25 June 2012 to 12 April 2016, the count stands at 40 filings.

The open-market side counts 1 purchase for €88k alongside 18 sales for €8.8M. On balance, insiders were net sellers of €8.7M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 6 share grants and 13 option exercises. So far in 2016, the count stands at 1 purchase and no sales.

On 12 April 2016 came the latest disclosure, an open-market purchase for €88k in Spyre Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.